IL316496A - B and T lymphocyte attenuator modulators (BTLA) and methods of using them - Google Patents
B and T lymphocyte attenuator modulators (BTLA) and methods of using themInfo
- Publication number
- IL316496A IL316496A IL316496A IL31649624A IL316496A IL 316496 A IL316496 A IL 316496A IL 316496 A IL316496 A IL 316496A IL 31649624 A IL31649624 A IL 31649624A IL 316496 A IL316496 A IL 316496A
- Authority
- IL
- Israel
- Prior art keywords
- btla
- modulators
- same
- lymphocyte attenuator
- attenuator
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Transplantation (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263335623P | 2022-04-27 | 2022-04-27 | |
| PCT/US2023/066258 WO2023212611A1 (en) | 2022-04-27 | 2023-04-26 | B and t lymphocyte attenuator (btla) modulators and method of using same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL316496A true IL316496A (en) | 2024-12-01 |
Family
ID=86558778
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL316496A IL316496A (en) | 2022-04-27 | 2023-04-26 | B and T lymphocyte attenuator modulators (BTLA) and methods of using them |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250282872A1 (enExample) |
| EP (1) | EP4514850A1 (enExample) |
| JP (1) | JP2025515337A (enExample) |
| KR (1) | KR20250007603A (enExample) |
| AU (1) | AU2023259623A1 (enExample) |
| CA (1) | CA3256715A1 (enExample) |
| IL (1) | IL316496A (enExample) |
| MX (1) | MX2024013146A (enExample) |
| WO (1) | WO2023212611A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2023004633A (es) * | 2020-10-23 | 2023-05-12 | Anaptysbio Inc | Moduladores del atenuador de linfocitos b y t (btla) y metodo de uso de los mismos. |
| WO2024243594A1 (en) * | 2023-05-25 | 2024-11-28 | Anaptysbio, Inc. | Btla agonist for mudulation of dendritic cells |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4828981A (en) | 1983-08-24 | 1989-05-09 | Synbiotics Corporation | Immunoassays for determining Dirofilaria immitis infection using antiidiotype monoclonal antibody reagents |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| ATE159548T1 (de) | 1990-11-13 | 1997-11-15 | Immunex Corp | Bifunktionelle wählbare fusionsgene |
| AU6953394A (en) | 1993-05-21 | 1994-12-20 | Targeted Genetics Corporation | Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene |
| US5464758A (en) | 1993-06-14 | 1995-11-07 | Gossen; Manfred | Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters |
| US5814618A (en) | 1993-06-14 | 1998-09-29 | Basf Aktiengesellschaft | Methods for regulating gene expression |
| FR2814642B1 (fr) | 2000-10-03 | 2005-07-01 | Ass Pour Le Dev De La Rech En | Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee |
| US7771951B2 (en) | 2001-12-03 | 2010-08-10 | Amgen Fremont Inc. | Antibody categorization based on binding characteristics |
| JP5675109B2 (ja) | 2007-02-20 | 2015-02-25 | アナプティスバイオ インコーポレイティッド | ライブラリーの生成方法及びその使用 |
| CA2769473A1 (en) * | 2009-07-31 | 2011-02-03 | N.V. Organon | Fully human antibodies to btla |
| MX2023004633A (es) * | 2020-10-23 | 2023-05-12 | Anaptysbio Inc | Moduladores del atenuador de linfocitos b y t (btla) y metodo de uso de los mismos. |
-
2023
- 2023-04-26 AU AU2023259623A patent/AU2023259623A1/en active Pending
- 2023-04-26 US US18/859,958 patent/US20250282872A1/en active Pending
- 2023-04-26 WO PCT/US2023/066258 patent/WO2023212611A1/en not_active Ceased
- 2023-04-26 EP EP23726259.7A patent/EP4514850A1/en active Pending
- 2023-04-26 IL IL316496A patent/IL316496A/en unknown
- 2023-04-26 JP JP2024563361A patent/JP2025515337A/ja active Pending
- 2023-04-26 KR KR1020247039407A patent/KR20250007603A/ko active Pending
- 2023-04-26 CA CA3256715A patent/CA3256715A1/en active Pending
-
2024
- 2024-10-24 MX MX2024013146A patent/MX2024013146A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023212611A1 (en) | 2023-11-02 |
| JP2025515337A (ja) | 2025-05-14 |
| CA3256715A1 (en) | 2023-11-02 |
| US20250282872A1 (en) | 2025-09-11 |
| KR20250007603A (ko) | 2025-01-14 |
| EP4514850A1 (en) | 2025-03-05 |
| MX2024013146A (es) | 2025-01-09 |
| AU2023259623A1 (en) | 2024-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4118766A4 (en) | COMMUNICATION APPARATUS AND METHOD FOR ENABLING TRANSMISSION OVER COMBINATIONS OF MULTIPLE RESOURCE UNITS | |
| EP4176664A4 (en) | METHOD AND DEVICE FOR TRANSMITTING UPLINK CHANNELS | |
| EP4598080A4 (en) | METHOD AND APPARATUS FOR CALLING RESOURCES | |
| EP4456639A4 (en) | RESOURCE DETERMINATION METHOD AND DEVICE | |
| EP4324277A4 (en) | METHODS AND APPARATUS FOR TX UL SWITCHING OF MULTIPLE TX ENCLOSURES | |
| EP4446915A4 (en) | APPLICATION MANAGEMENT METHOD AND ASSOCIATED DEVICE | |
| EP4523363A4 (en) | Method and device for determining the bandwidth for transmitting SRS resources | |
| DK4213595T3 (da) | Fremgangsmåde og system til dynamisk justering af pulsbreddemodulatorsignal, og system til dynamisk kontrol af højeffektlampe | |
| EP4429124A4 (en) | METHOD AND APPARATUS FOR BEAM MANAGEMENT | |
| EP4292353A4 (en) | Method and apparatus for resource allocation of mbs | |
| HK40123375A (en) | B and t lymphocyte attenuator (btla) modulators and method of using same | |
| HK40089992A (en) | B and t lymphocyte attenuator (btla) modulators and method of using same | |
| EP4503457A4 (en) | METHOD AND APPARATUS FOR DETERMINING EFFECTIVE TIME | |
| MX2024013146A (es) | Moduladores de atenuador de linfocitos b y t (btla) y método de uso de los mismos | |
| EP4184338A4 (en) | SYSTEM ARCHITECTURE SWITCHING METHOD AND APPARATUS | |
| EP4309454A4 (en) | Method and system of feedback for group common transmission | |
| WO2022087441A3 (en) | B and t lymphocyte attenuator (btla) modulators and method of using same | |
| EP4321838C0 (en) | METHOD FOR INSPECTION OF SURFACES AND INTERFACES OF HIGH-VOLTAGE CABLE COMPONENTS | |
| PT4176365T (pt) | Método para controlar o tempo que um indivíduo passa em frente de um ecrã | |
| EP4543130A4 (en) | METHOD AND SYSTEM FOR ESTABLISHING END-TO-END COMMUNICATION | |
| GB202319457D0 (en) | Method and system for predicting one or more attributes of test cases | |
| EP4522158A4 (en) | PAK1 DEGRADING AGENTS AND THEIR METHODS OF USE | |
| EP4509856A4 (en) | TEST SYSTEM AND ITS TEST METHOD | |
| EP4459429A4 (en) | AUGMENTED REALITY DEVICE SWITCHING INPUT MODE AND ASSOCIATED METHOD | |
| EP4163767A4 (en) | DEVICE AND METHOD FOR REDUCING OUTPUT DELAY OF TOUCH INPUT |